FeesSafety
Pluang+

Uwharrie Capital reports $10M net income for 9 months, assets rise to $1.23B by Sept 2026

Company Fundamentals
29 Oct 2026, 01:18 WIB
PRNewsWire
View Source
Bullish
Uwharrie Capital reports $10M net income for 9 months, assets rise to $1.23B by Sept 2026

Uwharrie Capital Corp and its subsidiary Uwharrie Bank reported consolidated total assets of $1.23 billion as of September 30, 2026, up from $1.20 billion at the end of 2025. The company earned a net income of $10.0 million for the first nine months of 2026, an increase from $8.3 million in the same period last year. Net income available to common shareholders was $9.6 million, or $1.31 per share, compared to $7.8 million, or $1.05 per share, in 2025. These results reflect steady growth and profitability for Uwharrie Capital, indicating a positive financial position moving forward.

Uwharrie Capital Corp's third quarter 2026 earnings report provides context for readers following financials. For readers following Financials-sector US stocks on Pluang, here is the market snapshot as of Oct 29, 2026 05:02 WIB: out of 142 priced stocks, 91 rose and 49 fell. Notable movers include GLXY at USD 18.83 with a 1-day change of +9.60% and a typical hold time of 8 days, BBD at USD 2.74 down 5.84% with 0% sell and 100% buy order activity, and BSBR at USD 4.56 down 5.79% with balanced order activity and a typical hold time of 5 days.

More News

China's coffee market to reach $8.04B by 2032, driven by cafe culture and specialty coffee growth.

China's coffee market to reach $8.04B by 2032, driven by cafe culture and specialty coffee growth.

China's coffee market is projected to grow from $5.8 billion in 2026 to $8.04 billion by 2032, at a CAGR of 5.54%. Growth is fueled by expanding chain cafes, specialty coffee methods like cold brew, and rising homegrown brands. However, rising coffee...

Market News
Neutral
1 hour ago
FDA grants orphan drug status to sovleplenib for rare autoimmune disease ITP treatment

FDA grants orphan drug status to sovleplenib for rare autoimmune disease ITP treatment

HUTCHMED announced that the US FDA has granted orphan drug designation to sovleplenib for treating primary immune thrombocytopenia (ITP), a rare autoimmune disorder causing low platelet counts and bleeding risks. This status provides benefits like 7 ...

Market News
Bullish
1 hour ago
LUXEED hosts global media test drive showcasing advanced tech and luxury in new LLounge and Stormax models.

LUXEED hosts global media test drive showcasing advanced tech and luxury in new LLounge and Stormax models.

LUXEED held a global media test drive event at Chery's International Headquarters in Vu Hồ, featuring the luxury MPV LLounge and the high-performance Stormax SUV. Media representatives and influencers from UAE, Thailand, and Indonesia experienced a 1...

Market News
Bullish
1 hour ago
Law firm investigates NVE Corporation over sharp Q2 revenue drop and stock plunge.

Law firm investigates NVE Corporation over sharp Q2 revenue drop and stock plunge.

Kirby McInerney LLP is investigating NVE Corporation for possible violations of federal securities laws after the company reported a 47% revenue decline and a 33.7% stock price drop following its Q2 fiscal 2027 results. The revenue fall was attribute...

Market News
Bearish
3 hours ago
Fort Technology warned by Nasdaq for falling below $1 minimum bid price, given 180 days to comply.

Fort Technology warned by Nasdaq for falling below $1 minimum bid price, given 180 days to comply.

Fort Technology received a notification from Nasdaq on October 13, 2026, stating it failed to meet the minimum bid price requirement of $1.00 per share over the past 30 days. The company has 180 days, until April 12, 2027, to restore its share price ...

Market News
Bearish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App